Unnamed: 0,title,date,stock,sentiment
835766.0,"Mallinckrodt Highlights Publication Of Findings From Medical Chart Study To Assess Use Of Terlipressin, Other Vasopressors In Hospitalized Patients With Hepatorenal Syndrome Type 1",2020-06-11 06:46:00-04:00,MNK,neutral
835767.0,Mallinckrodt Completes Rolling Submission Of Biologics License Application For Stratagraft Regenerative Skin Tissue To FDA,2020-06-09 06:32:00-04:00,MNK,neutral
835768.0,Mallinckrodt Will Appeal District Court Ruling in Case Involving Ongoing Acthar Medicaid Drug Rebate Dispute with the Centers for Medicare and Medicaid Services,2020-06-01 06:47:00-04:00,MNK,negative
835769.0,Mallinckrodt shares are trading lower after JP Morgan downgraded the company's stock from Neutral to Underweight.,2020-05-19 06:09:00-04:00,MNK,positive
835770.0,JP Morgan Downgrades Mallinckrodt to Underweight,2020-05-19 06:06:00-04:00,MNK,positive
835771.0,"New York Ag Says Will Issue New Subpoenas To Multiple Banks, Financial Institutions To Determine Where The Sacklers Stored Their Money Over The Years",2020-05-13 15:58:00-04:00,MNK,neutral
835772.0,"SVB Leerink Maintains Market Perform on Mallinckrodt, Raises Price Target of $3",2020-05-06 11:17:00-04:00,MNK,neutral
835773.0,Mallinckrodt shares are trading lower the company reported worse-than-expected Q1 sales.,2020-05-05 08:38:00-04:00,MNK,neutral
835774.0,"Mallinckrodt Q1 Adj. EPS $1.640 Beats $1.480 Estimate, Sales $665.800M Miss $693.310M Estimate",2020-05-05 06:46:00-04:00,MNK,negative
835775.0,Mallinckrodt's INOmax Study Ended Early Due to Achievement of its Primary Goal,2020-05-04 06:47:00-04:00,MNK,neutral
835776.0,Mallinckrodt Says Is Supporting Investigator-Initiated Study At Massachusetts General Hospital To Assess Effectiveness Of Inhaled Nitric Oxide In Patients With Severe Acute Respiratory Distress Syndrome Due To COVID-19,2020-04-30 08:05:00-04:00,MNK,negative
835777.0,Mallinckrodt shares are trading higher after the company announced the FDA has approved for review its New Drug Application for Terlipressin.,2020-04-22 07:30:00-04:00,MNK,positive
835778.0,Mallinckrodt Announces FDA Filing Acceptance Of New Drug Application For Terlipressin For Treatment Of Hepatorenal Syndrome Type 1 (HRS-1),2020-04-22 06:47:00-04:00,MNK,positive
835779.0,"Mallinckrodt Shares Relatively Quiet But Saw Large Volume Spike; Hearing New York Governor Cuomo Says Initiated Admin. Proceedings, Filed Charges Against Co. Related To Opioid Crisis",2020-04-21 12:00:00-04:00,MNK,negative
835780.0,"Mallinckrodt Highlights Publication Of Data On Acthar Gel (Repository Corticotropin Injection) From Its Randomized, Double-Blind, Placebo-Controlled Phase 4 Study In Rheumatoid Arthritis (RA) In Rheumatology And Therapy",2020-04-15 06:53:00-04:00,MNK,neutral
835781.0,"Mallinckrodt Shares Resume Trade, Tick To Pre-Market High Of $2.05, Pullback To $1.90 Level",2020-04-07 09:17:00-04:00,MNK,positive
835782.0,"Mallinckrodt 8-K Shows Details Of Indenture For Co. Organized Under Laws Of Grand Duchy Of Luxembourg, Dated Apr. 7, 2020",2020-04-07 09:01:00-04:00,MNK,positive
835783.0,UPDATE: Mallinckrodt Shares Halted With Code News Pending,2020-04-07 08:57:00-04:00,MNK,positive
835784.0,Mallinckrodt Shares Halted,2020-04-07 08:57:00-04:00,MNK,positive
835785.0,"CFRA Maintains Hold on Mallinckrodt, Lowers Price Target to $4",2020-04-01 12:08:00-04:00,MNK,negative
835786.0,Mallinckrodt PLC shares are trading higher after the company announced it received clearance from Health Canada to start on a  pilot trial of high dose inhaled nitric oxide therapy for coronavirus infection and associated lung complications.,2020-04-01 08:32:00-04:00,MNK,positive
835787.0,Mallinckrodt And Novoteris Receive Clearance From Health Canada To Start Pilot Trial Of High-Dose Inhaled Nitric Oxide Therapy For Coronavirus Infection And Associated Lung Complications,2020-04-01 06:47:00-04:00,MNK,neutral
835788.0,UPDATE: Defendants' Notice To Mallinckrodt Indicates CMS Action Could Delay Any Potential Suspension Of Co. From Medicaid Program Until Aug. 31,2020-03-18 13:33:00-04:00,MNK,negative
835789.0,Mallinckrodt Shares Fall To Session Low As Hearing Defendants In Acthar Case Informed Co. CMS To Refrain From Locking Co. Out Of Online Data Reporting System For Next 60 Days,2020-03-18 13:32:00-04:00,MNK,neutral
835790.0,Mallinckrodt Completes Rolling Submission Of New Drug Application To FDA Terlipressin ForTreatment Of Patients With Hepatorenal Syndrome Type 1 (HRS-1),2020-03-17 06:50:00-04:00,MNK,neutral
835791.0,"Mallinckrodt Evaluates the Potential Role for Inhaled Nitric Oxide to Treat COVID-19 Associated Lung Complications, Engages with Scientific, Governmental and Regulatory Agencies",2020-03-12 06:47:00-04:00,MNK,positive
835792.0,Mallinckrodt Announces NY State Attorney General Has Joined 47 Other State Attorneys In Supporting PReviously-Announced Opioid Settlement Against Co. And Related Entities,2020-03-11 06:05:00-04:00,MNK,positive
835793.0,"Mallinckrodt Highlights Publication Of New Data On Acthar Gel In Rheumatoid Arthritis, Systemic Lupus Erythematosus And Dermatomyositis/Polymyositis Published In Open Access Rheumatology: Research And Reviews",2020-03-04 06:49:00-05:00,MNK,neutral
835794.0,"Mallinckrodt Initiates Rolling Submission of New Drug Application to the FDA for Terlipressin for the Treatment of Patients with Hepatorenal Syndrome Type 1, Expects Complete New Drug Application Submission Within Coming Months",2020-03-02 06:48:00-05:00,MNK,neutral
835795.0,"B of A Securities Maintains Underperform on Mallinckrodt, Raises Price Target to $3",2020-02-26 12:36:00-05:00,MNK,positive
835796.0,"Benzinga Pro's Top 5 Stocks To Watch For Tues., Feb. 25, 2020: NIO, TUP, PANW, MRNA, MNK",2020-02-25 08:05:00-05:00,MNK,positive
835797.0,"Mallinckrodt Q4 Adj. EPS $2.40 Beats $2.05 Estimate, Sales $804.9M Beat $772.52M Estimate",2020-02-25 06:08:00-05:00,MNK,neutral
835798.0,UPDATE: Mallinckrodt Has Reached Agreement In Principle That Would Resolve All Opioid-Related Claims Against Co.,2020-02-25 06:03:00-05:00,MNK,positive
835799.0,Mallinckrodt Announces Agreement On Principle For Global Opioid Settlement And Associated Debt Refinancing Activities Through Chapter11 Filing By Certain Specialty Generics-Focused Subsidiaries; Plaintiffs Would Receive $1.6B,2020-02-25 06:02:00-05:00,MNK,positive
835800.0,"Mallinckrodt Shares Resume Trade, Continue To Rebound; Down 22% For Session",2020-02-24 15:01:00-05:00,MNK,positive
835801.0,Mallinckrodt Shares Halted To The Upside On Fifth Circuit Breaker,2020-02-24 14:57:00-05:00,MNK,positive
835802.0,"Mallinckrodt Shares Resume Trade, Rebound Sharply From Session Low, Up 52% From Low, Still Down 25% For Session",2020-02-24 14:56:00-05:00,MNK,negative
835803.0,"Mallinckrodt Shares Halted On Fourth Circuit Breaker, Down ~40% For Session",2020-02-24 14:46:00-05:00,MNK,positive
835804.0,Mallinckrodt Shares Halted On Circuit Breaker,2020-02-24 14:30:00-05:00,MNK,positive
835805.0,Mallinckrodt Shares Resume Trade,2020-02-24 14:28:00-05:00,MNK,positive
835806.0,"Mallinckrodt Shares Halted On Circuit Breaker, Down 11.3%",2020-02-24 14:23:00-05:00,MNK,positive
835807.0,CA Ag's Office Says 'Far Along In The Process Of Talks' And Still Negotiating With Distributors On Opioid Settlement,2020-02-14 12:24:00-05:00,MNK,neutral
835808.0,Shares of opioid-related companies are trading lower following reports suggesting 21 states have rejected an $18 billion offer to settle opioid litigation.,2020-02-14 10:15:00-05:00,MNK,negative
835809.0,"Mallinckrodt PLC shares are trading lower sympathy with the overall market as the Wuhan coronavirus continues to spread throughout the country, prompting travel bans in multiple Chinese cities. Reports say the death toll rose to 80 as of Sunday.",2020-01-27 09:26:00-05:00,MNK,negative
835810.0,Mallinckrodt shares are trading lower. Not currently seeing any company-specific news.,2020-01-24 11:02:00-05:00,MNK,neutral
835811.0,Mallinckrodt shares are trading lower. Not currently seeing any company-specific news.,2020-01-22 10:59:00-05:00,MNK,neutral
835812.0,Mallinckrodt shares are trading higher. Not seeing any news to justify the price action. NOTE: The stock has rallied approximately 84% over the past 5 trading sessions.,2020-01-21 11:17:00-05:00,MNK,positive
835813.0,"Mallinckrodt shares are trading higher on momentum following the company's Monday presentation at the JP Morgan Healthcare Conference, in which the company said it could pay off debt maturities and saw a favorable outcome in the Acthar dispute.",2020-01-16 10:41:00-05:00,MNK,positive
835814.0,Mallinckrodt PLC shares are trading higher on seemingly no company-specific news. NOTE: U.S. equities are trading higher ahead of today's signing of the U.S.-China phase one trade deal.,2020-01-15 11:42:00-05:00,MNK,neutral
835815.0,Mallinckrodt Announces First Patient Enrolled In Phase 4 Trial Of Acthar Gel For Severe Keratitis,2019-12-16 16:49:00-05:00,MNK,negative
835816.0,"S&P Sets CCC Rating On Mallinckrodt, Assigns Negative Outlook",2019-12-10 17:19:00-05:00,MNK,negative
835817.0,Mallinckrodt Announces Plans To Update Its Incentive Compensation Clawback Policy And Create Opioid Report; Actions Taken In Response To Approval Of Shareholder Proposals Presented At 2019 Annual General Meeting,2019-12-10 06:46:00-05:00,MNK,positive
835818.0,Mallinckrodt shares are trading lower amid weakness in the broader biotech space.,2019-12-05 11:43:00-05:00,MNK,negative
835819.0,"Benzinga Pro's Stocks To Watch For Wednesday, Nov. 27th, 2019: DE, ADSK, GES, MNK, AMZN",2019-11-27 08:42:00-05:00,MNK,neutral
835820.0,"Brooklyn Federal Prosecutors Open Criminal Probe Of Opioid Manufacturers, Distributors; Mallinckrodt, AmerisourceBergen, Johnson & Johnson and Amneal Say They Have Received Subpoenas",2019-11-26 12:51:00-05:00,MNK,negative
835821.0,Mallinckrodt Highlights Data On Acthar Gel For Symptomatic Sarcoidosis Published In Therapeutic Advances in Respiratory Disease,2019-11-26 06:52:00-05:00,MNK,neutral
835822.0,Mallinckrodt shares are trading higher. Not seeing any news to justify the price action.,2019-11-25 11:16:00-05:00,MNK,positive
835823.0,West Virginia Sues Opioid Makers Endo International And Mallinckrodt,2019-11-20 14:25:00-05:00,MNK,neutral
835824.0,Mallinckrodt Highlights Presentation Of New Clinical Data From Evaluating Acthar Gel In Rheumatoid Arthritis,2019-11-12 16:32:00-05:00,MNK,neutral
835825.0,Mallinckrodt Highlights Presentation Of Phase 3 Results From CONFIRM Study Of Terlipressin For HRS-1; Study Met Primary Endpoint,2019-11-11 15:31:00-05:00,MNK,neutral
835826.0,Mallinckrodt Announces Data Publication On The Treatment Effectiveness Of Acthar Gel For Resolution Of Multiple Sclerosis Relapse In A U.S. Health Plan Population,2019-11-07 09:39:00-05:00,MNK,neutral
835827.0,Mallinckrodt Highlights Publication Of Data On Treatment Effectiveness Of Acthar Gel For Resolution Of Multiple Sclerosis Relapse In US Health Plan Population,2019-11-07 07:16:00-05:00,MNK,neutral
835828.0,Mallinckrodt PLC shares are trading lower after the company reported worse-than-expected Q3 sales results.,2019-11-05 08:34:00-05:00,MNK,neutral
835829.0,Mallinckrodt Sees FY19 Adj. EPS $8.50-$8.70 vs $8.48 Est.,2019-11-05 06:12:00-05:00,MNK,neutral
835830.0,"Mallinckrodt Q3 Adj. EPS $2.07 Beats $1.98 Estimate, Sales $743.7M Miss $774.73M Estimate",2019-11-05 06:11:00-05:00,MNK,negative
835831.0,Mallinckrodt shares are trading higher. The stock has been volatile amid lawsuits against opioid-related companies this year.,2019-11-04 11:29:00-05:00,MNK,positive
835832.0,Mallinckrodt Announces UVADEX Approved In Australia For Use With The THERAKOS CELLEX Photopheresis System For Treatment Of Chronic Graft Versus Host Disease (cGvHD) And Skin Manifestations Of Cutaneous T-Cell Lymphoma (CTCL) In Adults,2019-10-31 16:36:00-04:00,MNK,positive
835833.0,Mallinckrodt shares are trading higher. Not seeing any news to justify the price action.,2019-10-23 13:35:00-04:00,MNK,positive
835834.0,Mallinckrodt PLC shares are trading higher on seemingly no company-specific news.,2019-10-22 14:17:00-04:00,MNK,neutral
835835.0,Mallinckrodt Shares Spike ~6% On Heavy Volume As Teva Confirms Settlement In Track 1 Opioid Case,2019-10-21 13:57:00-04:00,MNK,positive
835836.0,Mallinckrodt To Present Results From Its Pivotal Phase 3 Confirm Study Of Terlipressin In Patients With Hepatorenal Syndrome Type 1 (HRS-1) At The Liver Meeting 2019,2019-10-21 10:23:00-04:00,MNK,neutral
835837.0,Mallinckrodt Reports Will Present Results From Pivotal Phase 3 CONFIRM Study In Late-Breaking Session At The Liver Meeting,2019-10-21 10:16:00-04:00,MNK,neutral
835838.0,Shares of opioid-related drug companies are trading lower after the WSJ reported that a settlement has been reached in the opioid addiction lawsuit. The settlement is expected to be announced today.,2019-10-21 08:55:00-04:00,MNK,negative
835839.0,"Shares of opioid-associated drug distributors are trading higher on continued momentum after it was reported McKesson, AmerisourceBergen, and Cardinal Health are in talks to settle opioid litigation for $18 billion.",2019-10-17 09:43:00-04:00,MNK,positive
835840.0,Mallinckrodt PLC shares are trading lower on continued downward momentum. The stock has decreased roughly 30% in the last month.,2019-10-14 14:42:00-04:00,MNK,neutral
835841.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tuesday, October 01, 2019",2019-10-01 09:32:00-04:00,MNK,positive
835842.0,Mallinckrodt Announces Findings From Observational Registry To Assess Acthar Gel In MS Relapse; Results For Main Subsets Of Patients Were 'Highly Statistically Significant For All The Efficacy Endpoints',2019-10-01 06:46:00-04:00,MNK,positive
835843.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Monday, September 30, 2019",2019-09-30 11:31:00-04:00,MNK,positive
835844.0,Mallinckrodt shares are trading higher after the company announced it settled opioid cases in Cuyahoga and Summit counties in Ohio.,2019-09-30 07:55:00-04:00,MNK,positive
835845.0,"Mallinckrodt Finalizes Settlement to Resolve Opioid Cases with the Ohio Counties of Cuyahoga and Summit, Mallinckrodt to Pay $24M in Cash and $6M in Products",2019-09-30 06:50:00-04:00,MNK,positive
835846.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tuesday, September 24, 2019",2019-09-24 10:39:00-04:00,MNK,positive
835847.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Monday, September 23, 2019",2019-09-23 09:38:00-04:00,MNK,positive
835848.0,Mallinckrodt's Phase 3 Trial of StrataGraft Regenerative Tissue in Patients with Deep Partial-Thickness Thermal Burns Met Both Primary Endpoints,2019-09-23 06:49:00-04:00,MNK,neutral
835849.0,Mallinckrodt Highlights Findings From Analysis Suggesting Acthar Gel May Be A Cost-Effective Option Compared To Other Treatments For Multiple Sclerosis Relapse,2019-09-13 06:51:00-04:00,MNK,neutral
835850.0,"Mallinckrodt shares trading lower likely on continued profit taking following a 90% rally on Tuesday. Despite also paring gains on Wednesday, the stock is still up about 43% since announcing it will sell BioVectra to HIG Capital for $250 million.",2019-09-12 15:53:00-04:00,MNK,positive
835851.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Wednesday., September 11, 2019",2019-09-11 09:24:00-04:00,MNK,positive
835852.0,"Mallinckrodt PLC shares are trading lower as traders potentially took profits after the stock rose roughly 90% yesterday, following news that the company would sale  H.I.G. Capital for $250 million.",2019-09-11 09:21:00-04:00,MNK,positive
835853.0,Mallinckrodt CEO Says Co. Spends About $40M A Year On Dealing With Opioid Lawsuits,2019-09-10 08:12:00-04:00,MNK,negative
835854.0,Mallinckrodt To Sell BioVectra Inc. To H.I.G. Capital For $250M,2019-09-10 06:45:00-04:00,MNK,neutral
835855.0,"Stifel Maintains Hold on Mallinckrodt, Lowers Price Target to $8",2019-09-09 08:15:00-04:00,MNK,negative
835856.0,"Mallinckrodt shares trading higher following settlement in principle to resolve Track 1 opioid cases in Summit, Cuyahoga, Ohio. The company will pay $24 million in cash and donate $6 million in generic products.",2019-09-06 13:07:00-04:00,MNK,positive
835857.0,"Mallinckrodt Shares Resume Trade, Now Up 17% For Session",2019-09-06 12:37:00-04:00,MNK,positive
835858.0,"Mallinckrodt Announces Settlement In Principle To Resolve Track 1 Opioid Cases With Ohio Counties Of Cuyahoga And Summit; Co. To Pay $24M In Cash And Donate $6M In Generic Products, All Named Mallinckrodt Will Be Dismissed With Prejudice From Lawsuit",2019-09-06 12:22:00-04:00,MNK,negative
835859.0,"Mallinckrodt Shares Halted, News Pending",2019-09-06 12:19:00-04:00,MNK,positive
835860.0,Mallinckrodt shares are trading lower on a report that the company hired the restructuring firm Latham & Watkins in the wake of multiple looming lawsuits. BMO Capital also downgraded the stock from Outperform to Market Peform.﻿,2019-09-05 07:34:00-04:00,MNK,negative
835861.0,BMO Capital Downgrades Mallinckrodt to Market Perform,2019-09-05 06:42:00-04:00,MNK,neutral
835862.0,Mallinckrodt shares are trading lower on a report that the company hired the restructuring firm Latham & Watkins in the wake of multiple looming lawsuits.,2019-09-04 17:04:00-04:00,MNK,negative
835863.0,Mallinckrodt Shares Down 19% After Hours; Hearing Co. Hired Restructuring Firm Latham & Watkins,2019-09-04 16:59:00-04:00,MNK,positive
835864.0,"Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Wednesday., September 04, 2019",2019-09-04 12:39:00-04:00,MNK,positive
835865.0,"Mallinckrodt shares are trading lower after the company borrowed $95 million in revolving credit ""to address cash needs that may arise in the future.""",2019-08-30 15:48:00-04:00,MNK,positive
835866.0,"Barclays Maintains Equal-Weight on Mallinckrodt, Lowers Price Target to $5",2019-08-28 07:27:00-04:00,MNK,negative
835867.0,Mallinckrodt shares are trading lower after the company lost an appeal in the INOmax patent dispute with Praxair.,2019-08-27 12:19:00-04:00,MNK,negative
835868.0,Mallinckrodt Says Disappointed By Court's Decision Rejecting Patent Infringement Lawsuit Against Praxair's Nitric Oxide Drug Product Delivery System,2019-08-27 10:58:00-04:00,MNK,negative
835869.0,Mallinckrodt Reports Top-Line Results From Pivotal Phase 3 CONFIRM Trial Of Terlipressin In Patients With HRS-1: Met Primary Endpoint,2019-08-15 06:48:00-04:00,MNK,neutral
835870.0,Mallinckrodt Highlights Publication Of Results Of Phase 1b Trial Of StrataGraft Regenerative Tissue In Burns; Reports Burns Did Not Require Surgical Harvest Of Healthy Skin By 28 Days,2019-08-13 17:01:00-04:00,MNK,positive
835871.0,Shares of several healthcare companies are trading lower in sympathy with the overall market as the Treasury yield continues to decline along with ongoing trade tensions with China.,2019-08-12 15:33:00-04:00,MNK,positive
835872.0,"Mallinckrodt Reports First Patient Enrolled In Phase 2a Study Of MNK-6106 In Hepatic Cirrhosis, Chronic Hepatic Encephalopathy",2019-08-12 06:46:00-04:00,MNK,neutral
835873.0,Mallinckrodt PLC shares are trading lower despite the company reporting better-than-expected Q2 EPS and sales results. The company also reported FY19 EPS guidance above analyst estimates.,2019-08-07 10:29:00-04:00,MNK,neutral
835874.0,Mallinkcrodt Cites Multidistrict Opioid Litigation Case In Ohio As Partly Responsible For Decision Not To Spin Off Generics Business,2019-08-06 09:21:00-04:00,MNK,positive
835875.0,Mallinckrodt Sees FY19 Adj. EPS $8.40-$8.70 vs $8.24 Est.,2019-08-06 06:07:00-04:00,MNK,neutral
835876.0,"Mallinckrodt Q2 Adj. EPS $2.53 Beats $2.08 Estimate, Sales $823.3M Beat $815.9M Estimate",2019-08-06 06:06:00-04:00,MNK,neutral
835877.0,UPDATE: Mallinckrodt Will Make $5M Equity Investment In Silence Therapeutics,2019-07-18 06:48:00-04:00,MNK,neutral
835878.0,"Mallinckrodt, Silence Therapeutics Report Collaboration To Develop, Commercialize RNAi Therapeutics For Complement-Medicated Diseases",2019-07-18 06:47:00-04:00,MNK,neutral
835879.0,Mallinckrodt Reports Halted Phase 2B Trial On Use Of Acthar Gel In Amyotrophic Lateral Sclerosis,2019-07-16 17:21:00-04:00,MNK,neutral
835880.0,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.,2019-07-11 10:36:00-04:00,MNK,negative
835881.0,Mallinckrodt Announces 50% Enrollment for its Phase 2B Trial Investigating the Use of Acthar Gel in Amyotrophic Lateral Sclerosis,2019-06-24 06:56:00-04:00,MNK,neutral
835882.0,"Mallinckrodt Reports All Primary, Secondary Endpoints In Phase 4 Acthar Gel Rheumatoid Arthritis Trial, Will Present Data At EULAR",2019-06-13 06:50:00-04:00,MNK,neutral
835883.0,"Barclays Initiates Coverage On Mallinckrodt with Equal-Weight Rating, Announces $11 Price Target",2019-06-11 07:12:00-04:00,MNK,neutral
835884.0,BZ NOTE On Mallinckrodt Price Action Over Last Few Mins.: Seeing ~35.4% Short,2019-06-05 13:08:00-04:00,MNK,positive
835885.0,"Mallinckrodt Shares Resume Trade, Spike Sharply Higher, Now Up 7.6%",2019-06-05 13:03:00-04:00,MNK,positive
835886.0,"Mallinckrodt Shares Halted, News Pending",2019-06-05 12:43:00-04:00,MNK,positive
835887.0,"Piper Jaffray Downgrades Mallinckrodt to Neutral, Lowers Price Target to $9",2019-05-31 06:57:00-04:00,MNK,negative
835888.0,Mallinckrodt To Present Phase 4 Acthar Gel Clinical Trial Data At European Congress Of Rheumatology 2019,2019-05-29 06:57:00-04:00,MNK,neutral
835889.0,Mallinckrodt Provides Update On Plans For Company Separation And Spin-Off of Specialty Generics Business,2019-05-28 06:47:00-04:00,MNK,neutral
835890.0,"Jefferies Downgrades Mallinckrodt plc Ordinary Shares to Hold, Lowers Price Target to $15",2019-05-22 06:39:00-04:00,MNK,positive
835891.0,"Mallinckrodt shares trading lower following news the company filed suit against the US Department Of Health And Human Services, Centers For Medicare, Medicaid Services to protect Medicaid patient access to its Acthar gel.",2019-05-21 10:54:00-04:00,MNK,positive
835892.0,"Mallinckrodt Files Suit Against U.S. Department of Health and Human Services, and Centers for Medicare and Medicaid Services to Protect Medicaid Patient Access to Acthar® Gel",2019-05-21 07:03:00-04:00,MNK,positive
835893.0,Mallinckrodt Completes Enrollment If Phase 3 Terlipressin CONFIRM Trial,2019-05-14 06:58:00-04:00,MNK,neutral
835894.0,Mallinckrodt Raises FY19 Adj. EPS Guidance From $8.10-$8.40 To $8.30-$8.60 vs $8.21 Est.,2019-05-07 06:11:00-04:00,MNK,neutral
835895.0,"Mallinckrodt Q1 Adj. EPS $1.94 Beats $1.71 Estimate, Sales $790.6M Beat $768.6M Estimate",2019-05-07 06:10:00-04:00,MNK,neutral
835896.0,Mallinckrodt Reports Interim Analysis Results For Phase 4 Registry Of INOmax Gas For Inhalation For Pulmonary Hypertension In Neonates,2019-05-06 06:47:00-04:00,MNK,neutral
835897.0,Mallinckrodt To Present Open-Label Results From Phase 4 Acthar Gel Clinical Trial In Patients With Rheumatoid Arthritis At Annual European Congress Of Rheumatology In June,2019-05-02 08:45:00-04:00,MNK,neutral
835898.0,"Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'",2019-04-23 11:52:00-04:00,MNK,positive
835899.0,Mallinckrodt Reports Lupus Phase 4 Study For Acthar Gel Completes Enrollment In Difficult-To-Manage Population,2019-04-23 06:46:00-04:00,MNK,neutral
835900.0,Mallinckrodt Reports Top-Line Results From Proof-of-Concept Study of Nitric Oxide Gas in Ex-Vivo System of Human Lung Transplants: 'Study showed oxygenation improvement and increased out-of-body perfusion duration',2019-04-18 06:48:00-04:00,MNK,positive
835901.0,Mallinckrodt Reports Completion Of Full Enrollment Of Phase 3 Trial For StrataGraft,2019-04-12 06:45:00-04:00,MNK,neutral
835902.0,Mallinckrodt And Washington University St. Louis Select First Collaborative Research Endeavor,2019-04-11 06:45:00-04:00,MNK,neutral
835903.0,Mallinckrodt Gives an Update on its Acthar Gel,2019-04-09 06:50:00-04:00,MNK,neutral
835904.0,"SunTrust Robinson Humphrey Initiates Coverage On Mallinckrodt with Hold Rating, Announces $23 Price Target",2019-03-20 08:05:00-04:00,MNK,neutral
835905.0,Mallinckrodt Announces Bryan Reasons CFO,2019-03-18 06:47:00-04:00,MNK,neutral
835906.0,Mallinckrodt shares are trading higher after the company reported better than expected Q4 results and announced strong 2019 guidance.,2019-02-26 09:02:00-05:00,MNK,positive
835907.0,"Mallinckrodt Sees FY19 Adj. EPS $8.10-$8.40 vs $7.37 Estimate, Sales Growth For Special Brands, Specialty Generics, Amitiza Units 1-4%",2019-02-26 06:09:00-05:00,MNK,positive
835908.0,"Mallinckrodt Q4 EPS $2.18 Beats $1.92 Estimate, Sales $834.9M Beat $636.7M Estimate",2019-02-26 06:08:00-05:00,MNK,neutral
835909.0,Mallinckrodt Announces Extracorporeal Photopheresis Research Collaboration Agreement With Transimmune,2019-02-25 06:58:00-05:00,MNK,positive
835910.0,Mallinckrodt Announces Interim Analysis Results For Therakos Platform Phase 3 Clinical Trial In Treatment Of Pediatric Patients With Steroid Refractory Acute Graft-versus-Host Disease; Overall Response Rate Exceeded Specified Study Midpoint Target,2019-02-20 07:03:00-05:00,MNK,neutral
835911.0,Mallinckrodt Offers Update On Phase 4 Data HP Acthar Gel: 'primary end point results consistent with prior reports that showed 61% of patients with persistently active RA reported in the open-label period achieved low disease activity',2019-02-05 07:03:00-05:00,MNK,positive
835912.0,Mallinckrodt Reports Data From Its HP Acthar Gel In Patients  with Rare Cause of Nephrotic Syndrome Published in Transplantation,2019-01-03 06:36:00-05:00,MNK,neutral
835913.0,Mallinckrodt And NPXe Announce First Patient Enrolled In Phase 3 Trial Of Inhaled Xenon Gas Therapy;,2018-12-21 06:46:00-05:00,MNK,neutral
835914.0,"Mallinckrodt shares are now trading slightly higher, rebounding from premarket losses after the FDA informed the company that its New Drug Application for Roxicodone will need additional evaluation.",2018-12-12 10:21:00-05:00,MNK,negative
835915.0,Mallinckrodt shares are trading lower after the FDA informed Mallinckrodt that its New Drug Application for Roxicodone will need additional evaluation.,2018-12-12 09:01:00-05:00,MNK,neutral
835916.0,"Mallinckrodt's SpecGx Receives FDA Complete Response Letter for Abuse-Deterrent, Immediate-Release Reformulation Of Roxicodone; In Letter, FDA Provided Guidance Regarding Areas Needing Further Evaluation For Resubmission",2018-12-12 06:46:00-05:00,MNK,neutral
835917.0,"UPDATE: Mallinckrodt Says Spun Off Specialty Generics Unit Will Be Listed On NYSE, Will Assume Mallinckrodt Name, Ticker Symbol",2018-12-06 06:07:00-05:00,MNK,neutral
835918.0,UPDATE: Mallinckrodt Says Planned Separation Of Specialty Generics Unit To Be Executed Through Pro-Rata Distribution Of Common Stock To Co.'s Shareholders; Spin Off Expected To Be Completed In 2H'19 Or Sooner,2018-12-06 06:07:00-05:00,MNK,neutral
835919.0,Mallinckrodt Reports Spin Off Of Its Specialty Generics Unit,2018-12-06 06:05:00-05:00,MNK,neutral
835920.0,"'More $MNK failed clinical studies comes weeks after OIG publishes that Acthar is a drug based on a history of ""fraud and abuse. Citron believes that $MNK could be first pharma to go BK if Medicare opens its eyes' -Citron Research Tweets",2018-11-26 14:09:00-05:00,MNK,negative
835921.0,'$MNK has just FAILED it's only real clinical trial of Acthar. Mallinckrodt has failed to disclose.  Citron will follow with the full story on why the OIG and MEDPAC are finally about to put an end to this charade.' -Citron Research Tweets,2018-11-26 13:57:00-05:00,MNK,negative
835922.0,"Canaccord Genuity Upgrades Mallinckrodt to Buy, Raises Price Target to $40",2018-11-19 07:21:00-05:00,MNK,neutral
835923.0,"Mallinckrodt's SpecGx Reports FDA Voted 10-7 To Approve Its Abuse-Deterrent Roxicodone; Committee Voted 12-5 To Label Drug As Abuse-Deterrent By Nasal Route, Voted 10-7 Drug Should Not Be Labeled Abuse-Deterrent By Intravenous Route",2018-11-14 17:24:00-05:00,MNK,neutral
835924.0,"13F From Paulson & Co. Shows Liquidated Stakes In Vistra Energy, CenturyLink, Raises Stakes In NXP Semi, Aetna, Altaba, Cut Stakes In T-Mobile, Mallinckrodt, AT&T",2018-11-14 12:16:00-05:00,MNK,neutral
835925.0,"Mallinckrodt Reports Earned Int'l. Standard ISO 13485:2016, Medical Device Single Audit Program Certifications For INOmax DSIR Plus Nitric Oxide Delivery Systems",2018-11-08 06:48:00-05:00,MNK,neutral
835926.0,Mallinckrodt PLC Sees FY18 Adj. EPS $7.00-$7.20 vs $6.75 Est.,2018-11-06 06:28:00-05:00,MNK,neutral
835927.0,"Mallinckrodt PLC Q3 Adj. EPS $2.10 Beats $1.79 Estimate, Sales $640M Beat $634.52M Estimate",2018-11-06 06:27:00-05:00,MNK,neutral
835928.0,"Mallinckrodt Reports First Patient Screened In Phase 4 Trial Of HP Acthar Gel For Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis",2018-10-26 06:47:00-04:00,MNK,negative
835929.0,Mallinckrodt Presents Data on H.P. Acthar Gel in Rheumatoid Arthritis at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting,2018-10-22 06:55:00-04:00,MNK,neutral
835930.0,"Benzinga Pro's Top 10 Most-Searched Tickers For The Morning Of Mon., Oct. 15, 2018",2018-10-15 10:42:00-04:00,MNK,positive
835931.0,Mallinckrodt's Stratatech Company Awarded $26M in Additional BARDA Funding for Pediatric Studies of StrataGraft Skin Tissue in Thermal Burns,2018-10-15 06:45:00-04:00,MNK,positive
835932.0,13G Filing Shows Mallinckrodt Reporting 5.1% Stake Taken By D.E. Shaw,2018-10-12 16:06:00-04:00,MNK,neutral
835933.0,FDA Commissioner Scott Gottlieb Issues Statement On 'new efforts to advance the development of generic copies of complex drugs to improve patient access to medicines',2018-10-09 11:19:00-04:00,MNK,positive
835934.0,Mallinckrodt Announces the FDA Will Hold a Meeting of its Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee on Nov. 14 to Assess the 505(b)2 New Drug Application,2018-10-08 06:46:00-04:00,MNK,positive
835935.0,"Hearing Stifel Out In Defense Of Mallinckrodt, Says Praxair System Will Be Another Branded Competitor, Not A Generic Substitute",2018-10-04 13:08:00-04:00,MNK,positive
835936.0,Mallinckrodt Option Alert: Oct 19 $31 Calls Sweep (18) near the Ask: 500 @ $1.2 vs 59 OI; Earnings 11/6 Before Open [est] Ref=$29.835,2018-09-21 13:58:00-04:00,MNK,positive
835937.0,"FDA Issues New Safety Measures For Immediate-Release, Extended-Release, and Long-Acting Opioid Analgesics",2018-09-18 15:17:00-04:00,MNK,positive
835938.0,"Berenberg Initiates Coverage On Mallinckrodt with Sell Rating, Announces $25 Price Target",2018-09-14 08:37:00-04:00,MNK,neutral
835939.0,"Goldman Sachs Downgrades Mallinckrodt to Sell, Raises Price Target to $28",2018-09-11 08:35:00-04:00,MNK,neutral
835940.0,"Mallinckrodt And NPXe Announce FDA Fast Track Designation For Phase 3 Trial Of Inhaled Xenon Gas Therapy, Trial To Commence In The Coming Months With The First Patients Enrolled In The U.S.",2018-08-23 06:49:00-04:00,MNK,neutral
835941.0,Mallinckrodt Confirms Receipt Of Complete Response Letter Stannsoporfin,2018-08-22 06:46:00-04:00,MNK,neutral
835942.0,REMINDER: Mallinckrodt Has FDA PDUFA Decision Date Today for Stannsoporfin; BZ NOTE: FDA AdCom Meeting May 3rd Voted 3-21 Against Approval,2018-08-22 06:19:00-04:00,MNK,positive
835943.0,"Morgan Stanley Maintains Equal-Weight on Mallinckrodt, Raises Price Target to $35",2018-08-17 07:29:00-04:00,MNK,neutral
835944.0,"Barclays Maintains Underweight on Mallinckrodt, Raises Price Target to $20",2018-08-08 09:02:00-04:00,MNK,neutral
835945.0,"Stifel Nicolaus Maintains Hold on Mallinckrodt, Raises Price Target to $30",2018-08-08 07:20:00-04:00,MNK,neutral
835946.0,Raymond James Downgrades Mallinckrodt to Market Perform,2018-08-08 06:40:00-04:00,MNK,neutral
835947.0,Mallinckrodt Raises FY18 Adj. EPS Outlook From $6.50-$6.90 vs $6.23 Est.,2018-08-07 06:32:00-04:00,MNK,neutral
835948.0,"Mallinckrodt Q2 Adj. EPS $1.78 Beats $1.48 Estimate, Sales $631.7M Beat $620.42M Estimate",2018-08-07 06:30:00-04:00,MNK,neutral
835949.0,Mallinckrodt Forms Collaborative Research Partnership With Washington University in St. Louis With Focus On Rare Disease; Co. Fund Up To $10M In Research Grants Over 5-yr Period,2018-08-06 08:07:00-04:00,MNK,positive
835950.0,Mallinckrodt Announces Enrollment of the First Patient in its Phase 2 Duchenne Muscular Dystrophy Trial,2018-08-02 07:32:00-04:00,MNK,neutral
835951.0,Mallinckrodt Initiates Proof-of-Concept Study of Nitric Oxide Gas in Ex-Vivo System of Human Lung Transplants,2018-08-01 16:47:00-04:00,MNK,neutral
835952.0,"Canaccord Genuity Maintains Hold on Mallinckrodt, Raises Price Target to $22",2018-07-19 08:08:00-04:00,MNK,neutral
835953.0,New Health Economic Data on Mallinckrodt's OFIRMEV Injection Published in Journal of Knee Surgery,2018-07-09 06:34:00-04:00,MNK,neutral
835954.0,Mallinckrodt Option Alert: Aug 17 $15 Puts Sweep (3) near the Ask: 12191 @ $0.901 vs 46 OI; Earnings 8/7 Before Open [est] Ref=$18.9,2018-06-29 15:22:00-04:00,MNK,positive
835955.0,Mallinckrodt Option Alert: Jan 18 $15 Puts Sweep (18) near the Ask: 550 @ $1.798 vs 5175 OI; Earnings 8/7 Before Open [est] Ref=$18.97,2018-06-29 15:20:00-04:00,MNK,positive
835956.0,Mallinckrodt Option Alert: Aug 17 $12.5 Puts Sweep (21) near the Ask: 973 @ $0.346 vs 0 OI; Earnings 8/7 Before Open [est] Ref=$18.99,2018-06-29 15:20:00-04:00,MNK,positive
835957.0,Traders Circulating Negative CNN Article On Mallinckrodt's Acthar Gel Titled 'Medicare spent $2 billion for one drug as the manufacturer paid doctors millions',2018-06-29 13:43:00-04:00,MNK,negative
835958.0,Mallinckrodt Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar Gel  Achieves its Enrollment Target,2018-06-28 16:46:00-04:00,MNK,neutral
835959.0,"Mallinckrodt Up 0.5% At $19.08, Hearing Suntrust Raised Mallinckrodt Price Target From $14 To $25",2018-06-18 12:18:00-04:00,MNK,neutral
835960.0,Mallinckrodt Reports Interim Findings Of H.P. Acthar Gel Studies,2018-06-18 06:33:00-04:00,MNK,neutral
835961.0,BioDelivery Sciences Announces Agreement with Broadfin Capital on Comprehensive Plan to Strengthen Business By Reconstructing The Board; Also Announced A $50M Equity Financing Deal Led By Broadfin,2018-05-17 08:06:00-04:00,MNK,positive
835962.0,"Mallinckrodt Q2 EPS $1.31 Beats $1.10 Estimate, Sales $572.6M Beat $569.61M Estimate",2018-05-08 06:06:00-04:00,MNK,neutral
835963.0,Mallinckrodt Pharma Posts a Response to 60 Minutes Regarding its HP Acthar Gel,2018-05-07 07:01:00-04:00,MNK,neutral
835964.0,"UPDATE: Mallinckrodt Is Not Specifically Mentioned In CBSpressexpress.com Listings For Sun., May 6 '60 Minutes'; However, Site Does Highlight 'The Rockford File' Describing City Of Rockford, Illinois Suit Against Co.",2018-05-04 09:47:00-04:00,MNK,positive
835965.0,Mallinckrodt Shares Largely Unaffected As Traders Circulate Word Of Negative '60 Minutes' Piece This Sunday,2018-05-04 09:34:00-04:00,MNK,negative
835966.0,"Stocks That Made New 52-Week Lows Today Include Colgate-Palmolive, Philip Morris, Regeneron, Corning, Hanesbrands, Bed Bath & Beyond, Pepsi, Coca-Cola, Paccar, Johnson & Johnson, Mallinckrodt, CBS, DISH Network, Goodyear Tire, Chubb, Hershey, and AT&T",2018-05-03 11:31:00-04:00,MNK,negative
835967.0,REMINDER: Mallinckrodt Has FDA AdCom Mtg. Today for Stannsoporfin,2018-05-03 07:26:00-04:00,MNK,neutral
835968.0,"B. Riley FBR Initiates Coverage On Mallinckrodt with Neutral Rating, Announces $15 Price Target",2018-05-02 08:50:00-04:00,MNK,neutral
835969.0,"Stocks That Made New 52-Week Low Today Include: CBS, Goodyear Tire, Vulcan Materials, Regeneron, Hershey, Leggett & Platt, Harley-Davidson, Kraft Heinz, Kellogg, Mallinckrodt, Fortune Brands Home, Comcast, Pepsi, and Acuity Brands",2018-05-01 10:33:00-04:00,MNK,negative
835970.0,"Stocks That Made New 52-Week Lows Today Include: Kimberly-Clark, Philip-Morris, CenterPoint Energy, Fortune Brands Home, Mallinckrodt, Clorox, Bristol-Myers, Simon Property Group, Pepsi, Kimco Realty, Hasbro, and Procter & Gamble",2018-04-23 11:27:00-04:00,MNK,positive
835971.0,"Mallinckrodt Reports $300M Repayment Of Unsecured, Fixed-Rate Notes Maturing Apr. 15, 2018 With Cash On Hand",2018-04-16 16:31:00-04:00,MNK,positive
835972.0,Stifel Nicolaus Downgrades Mallinckrodt to Hold,2018-04-12 13:44:00-04:00,MNK,neutral
835973.0,Shares Of Mallinckrodt Down 8.6% Following Chatter Of Stifel Downgrade,2018-04-12 13:38:00-04:00,MNK,positive
835974.0,UPDATE: Wells Fargo Says Mallinckrodt Has Indicated It Will Defend Itself 'Vigorously',2018-04-12 11:59:00-04:00,MNK,positive
835975.0,"Mallinckrodt Shares Down 7.5%; Wells Fargo Highlights News Of Whistleblower Suit Being Made Public, Says Spoke With Co. Investor Relations And Mgmt. 'Strongly Disagrees' With Allegations",2018-04-12 11:59:00-04:00,MNK,positive
835976.0,"SunTrust Robinson Humphrey Initiates Coverage On Mallinckrodt with Hold Rating, Announces $15.00 Price Target",2018-04-12 07:14:00-04:00,MNK,neutral
835977.0,Angus Russell to Succeed Melvin Booth as Mallinckrodt Chairman of the Board in May 2018,2018-04-04 06:19:00-04:00,MNK,positive
835978.0,"Stocks That Made New 52-Wk Lows Today Include: Incyte, Merck, Mallinckrodt, Celgene, Cerner, Willams Cos., AMD, Albemarle, Kinder Morgan, Western Union, Walgreens, Kraft Heinz, Nielsen, and Alliance Data Systems",2018-04-03 12:15:00-04:00,MNK,positive
835979.0,"Stocks That Made New 52-Wk Lows Today Include: Johnson Controls, Exxon Mobile, Walgreens, Mallinckrodt, Hasbro, AMD, General Mills, Goodyear Tire, Whirlpool, Kraft Heinz, AIG, and Signet Jewelers",2018-04-02 14:58:00-04:00,MNK,negative
835980.0,"Mallinckrodt To Report Q1 Earnings On Tues., May 8, 2018 Before Market Open",2018-03-28 06:35:00-04:00,MNK,neutral
835981.0,"Benzinga Pro's Top 10 Most-Searched Tickers Wed. Morning: Square, Lipocine, Macy's, Mallinckrodt, Tetraphase Pharma, Zosano Pharma, Arcadia Biosciences, DelMar Pharma, Akers Biosciences, Acorn",2018-02-28 07:17:00-05:00,MNK,positive
835982.0,Mallinckrodt Shares Up 25% Following Strong Q4 Earnings Beat But FY18 EPS Guidance Below Estimates,2018-02-27 11:28:00-05:00,MNK,positive
835983.0,"Mallinckrodt FY18 EPS $6.00-$6.50 vs $7.14 Est., Sales Growth Of 3-6%",2018-02-27 06:07:00-05:00,MNK,positive
835984.0,"Mallinckrodt Reports Q4 EPS $2.01 vs $1.69 Est., Sales $792M vs $774M Est.",2018-02-27 06:07:00-05:00,MNK,neutral
835985.0,Mallinckrodt Reports Received FDA Acceptance Of Stannsoporfin NDA Filing,2018-02-23 06:57:00-05:00,MNK,positive
835986.0,Mallinckrodt Enrolls First Patient in Phase 1 Study of ExpressGraft C9T1 Skin Tissue,2018-02-14 06:35:00-05:00,MNK,neutral
835987.0,"S&P Dow Jones Indices Reports 'Boyd Gaming Set to Join S&P MidCap 400; Ring
Energy, James River Group Holdings and EVERTEC to Join S&P SmallCap 600'",2018-02-06 17:33:00-05:00,MNK,positive
835988.0,Barclays Downgrades Mallinckrodt to Underweight,2018-02-02 06:48:00-05:00,MNK,neutral
835989.0,Mallinckrodt Announces First Patient Enrolled In Phase 4 Trial Of HP Acthat Gel For Pulmonary Sarcoidosis,2018-01-30 16:47:00-05:00,MNK,neutral
835990.0,"Cantor Out With Note On Endo, Says Oxymorphone Subpoena May Not Hurt That Much And Is Isolated To Endo For Now, But More Co.'s Could Be The Target To Investigations Over Time Including Teva, Mylan, Impax, Mallinckrodt, Allergan",2018-01-11 11:18:00-05:00,MNK,positive
835991.0,"UPDATE: Mallinckrodt, Baxter Deal For RECOTHROM, PREVELEAK Will Include Upfront Payment Of $153M",2018-01-08 07:46:00-05:00,MNK,neutral
835992.0,"Mallinckrodt Reports Will Sell RECOTHROM, PREVELEAK To Baxter For ~$185M",2018-01-08 07:45:00-05:00,MNK,neutral
835993.0,Mallinckrodt Completes Stannsoporfin NDA,2018-01-04 16:46:00-05:00,MNK,neutral
835994.0,"Leerink Swann Initiates Coverage On Mallinckrodt with Market Perform Rating, Announces $26.00 Price Target",2018-01-03 08:38:00-05:00,MNK,neutral
835995.0,"Maxim Says They're Disappointed In Sucampo Pharmaceuticals Takeout Value, But Believes All Interested Parties On Sucampo's Side Will See Deal As A 'Happy Exit'; Believes Mallinckrodt Is Receiving A Great Deal For Co. At This Stage",2017-12-27 08:33:00-05:00,MNK,positive
835996.0,"Cantor Out Positive On Mallincrkodt, Says Sucampo Deal Was Smart And Strategic; Helps Co. Advance Towards Vision Of Becoming An 'Innovation-Driven specialty Pharmaceutical Growth Company'",2017-12-26 11:41:00-05:00,MNK,positive
835997.0,Mallinckrodt's Acquisition of Sucampo is a Cash Offer,2017-12-26 06:47:00-05:00,MNK,neutral
835998.0,Mallinckrodt to Acquire Sucampo Pharma for $18/Share,2017-12-26 06:46:00-05:00,MNK,neutral
835999.0,"Mallinckrodt Says the New Tax Bill Will be Neutral to Slightly Positive for the Company, Sees a Deferred Tax Benefit for $450M to $500M",2017-12-22 08:02:00-05:00,MNK,positive
836000.0,"Mallinckrodt Halted, News Pending",2017-12-22 07:59:00-05:00,MNK,neutral
836001.0,"Mallinckrodt, Insys Move Lower; Hearing Traders Circulating Chatter That New Mexico Is Suing Companies Over Opioid Epidemic",2017-12-20 15:20:00-05:00,MNK,negative
836002.0,UPDATE: Mallinckrodt Sees Dilution From Ocrea Purchase To Adj. EPS $0.25-$0.35 Annually Beginning In '18,2017-12-11 09:22:00-05:00,MNK,neutral
836003.0,Mallinckrodt Reports Closing Of Ocera Therapeutics Deal,2017-12-11 09:21:00-05:00,MNK,neutral
836004.0,Oppenheimer Downgrades Mallinckrodt PLC to Perform,2017-11-22 08:35:00-05:00,MNK,neutral
836005.0,Form 4 Filing Shows Mallinckrodt Director Booth Purchased 10K Shares At Weighted Avg. Price $21.8236,2017-11-13 17:47:00-05:00,MNK,positive
836006.0,"Form 4 Filings Show Mallinckrodt Director Gulyas Purchased 1.5K Shares At $21.30, Director Zaccagnino Purchased 5K Shares AT $21.30",2017-11-13 17:46:00-05:00,MNK,positive
836007.0,Form 4 Filing Shows Mallinckrodt Director Reed Purchased 1K Shares At $21.50,2017-11-13 17:45:00-05:00,MNK,positive
836008.0,"Form 4 Filing Shows Mallinckrodt EVP, Chief Scientific Officer Romano Purchased 2K Shares At $21.96",2017-11-13 17:42:00-05:00,MNK,positive
836009.0,James Flynn Reports 6.07% Stake In Mallinckrodt,2017-11-13 08:30:00-05:00,MNK,neutral
836010.0,"Canaccord Genuity Maintains Hold on Mallinckrodt PLC, Lowers Price Target to $24.00",2017-11-08 10:56:00-05:00,MNK,negative
836011.0,"Morgan Stanley Maintains Equal-Weight on Mallinckrodt PLC, Lowers Price Target to $27.00",2017-11-08 08:16:00-05:00,MNK,negative
836012.0,Goldman Sachs Downgrades Mallinckrodt PLC to Neutral,2017-11-08 08:15:00-05:00,MNK,neutral
836013.0,Wells Fargo Downgrades Mallinckrodt PLC to Market Perform,2017-11-08 07:59:00-05:00,MNK,positive
836014.0,"Stifel Nicolaus Maintains Buy on Mallinckrodt PLC, Lowers Price Target to $50.00",2017-11-08 07:46:00-05:00,MNK,negative
836015.0,Barclays Downgrades Mallinckrodt PLC to Equal-Weight,2017-11-08 06:53:00-05:00,MNK,neutral
836016.0,"Unconfirmed, Hearing Mallinckrodt Downgraded At Deutsche Bank",2017-11-07 11:58:00-05:00,MNK,negative
836017.0,"Mallinckrodt Q3 Adj. EPS $1.97 vs $1.81 Est., Sales $793.9M vs $812.0M Est.",2017-11-07 06:06:00-05:00,MNK,neutral
836018.0,Ocera Therapeutics Shares Up 66% Following $1.52/Share Offer From Mallinckrodt; Stock Currently Trading 11% Above Offer Price,2017-11-02 14:28:00-04:00,MNK,positive
836019.0,Ocerta Therapeutics to be Acquired by Mallinckrodt for $1.52/Share,2017-11-02 06:51:00-04:00,MNK,neutral
836020.0,Mallinckrodt Says it Will do a Phase 4 Study of HP Acthar Gel,2017-10-09 06:21:00-04:00,MNK,neutral
836021.0,Canaccord Genuity Downgrades Mallinckrodt plc Ordinary Shares to Hold,2017-10-05 06:50:00-04:00,MNK,positive
836022.0,"Mallinckrodt Downgraded From Buy To Hold At Canaccord Genuity, Price Target Cut From $77 To $40 - Reuters",2017-10-04 17:15:00-04:00,MNK,negative
836023.0,REMINDER: Mallinckrodt Holding Investor Briefing Today 9:30am ET,2017-10-04 09:11:00-04:00,MNK,neutral
836024.0,Mallinckrodt Expects its Total Pipeline Net Sales to Exceed $1B,2017-10-04 07:03:00-04:00,MNK,neutral
836025.0,Mallinckrodt Expects Net Sales of Near-Term Development Programs to Exceed $675M,2017-10-04 07:02:00-04:00,MNK,neutral
836026.0,UPDATE: Mallinckrodt Sees Dilution Of $0.10-$0.15/Share To Adj. EPS Figure For Remainder Of 2017; Sees Modestly Lower Dilution In 2018,2017-10-02 06:56:00-04:00,MNK,negative
836027.0,"UPDATE: Mallinckrodt Says NeuroproteXeon Will Receive Upfront Payment Of $10M From Co.; Includes Added Payments Of Up To $25M Dependent On Development, Regulatory, Sales Milestones",2017-10-02 06:55:00-04:00,MNK,neutral
836028.0,UPDATE: Mallinckrodt Highlights FDA SPA Approved For Phase 3 Trial Will Begin In Early 2018; FDA Orphan Drug Designation Granted For Inhaled Xenon Gas Therapy,2017-10-02 06:54:00-04:00,MNK,positive
836029.0,Mallinckrodt Reports Licensing Of Inhaled Xenon Gas Therapy Development Product,2017-10-02 06:53:00-04:00,MNK,neutral
836030.0,"Goldman Sachs Initiates Coverage On Mallinckrodt plc Ordinary Shares with Buy Rating, Announces $55.00 Price Target",2017-09-28 07:51:00-04:00,MNK,positive
836031.0,Mallinckrodt Shares Earlier Moved Up As Much As 3.5% Following Circulation Of Chatter Co. Cancelled Out Of Deutsche Bank Conference; BZ NOTE: Numerous Cos. Cancelled Out Of Presentation -- At Least 45 Cos.,2017-09-14 14:20:00-04:00,MNK,positive
836032.0,UPDATE: Hearing Mallinckrodt Chatter Related To Co. Cancelling Presentation For Deutsche Bank,2017-09-14 10:50:00-04:00,MNK,negative
836033.0,"Mizuho Downgrades Mallinckrodt plc Ordinary Shares to Neutral, Lowers Price Target to $40.00",2017-09-13 07:05:00-04:00,MNK,positive
836034.0,"Mallinckrodt Shares Turn Negative, Down ~0.2% For Session As Kynikos' Jim Chanos Currently On CNBC's 'Fast Money: Halftime Report' Discussing Co./Stock",2017-09-12 12:47:00-04:00,MNK,negative
836035.0,Morgan Stanley Downgrades Mallinckrodt plc Ordinary Shares to Equal-Weight,2017-09-06 07:23:00-04:00,MNK,positive
836036.0,"Mallinckrodt Q2 EPS $0.72 vs $1.73 Est., Sales $824.5M vs $829.6M Est., May Not Compare",2017-08-08 06:07:00-04:00,MNK,neutral
836037.0,"Mallinckrodt Reports InfaCare Pharma And Stannsoporfin For Upfront Payment Of $80M Plus Added Payments Of $345M Upon Regulatory, Sales Milestones",2017-08-04 07:01:00-04:00,MNK,neutral
836038.0,Mallinckrodt Enrolls Initial Patient In Phase 4 Registry Of INOMAX Gas For Inhalation For Pulmonary Hypertension In Neonates,2017-08-01 07:45:00-04:00,MNK,neutral
836039.0,"UPDATE: ResMed, Packaging Corp. Of America, AO Smith, Duke Realty To Replace Mallinckrodt, Murphy Oil, Bed Bath & Beyond, Transocean In S&P 500",2017-07-19 17:18:00-04:00,MNK,neutral
836040.0,Mallinckrodt's StrataGraft is Designated as Regenerative Medicine Advanced Therapy by the FDA,2017-07-18 07:06:00-04:00,MNK,positive
836041.0,Mallinckrodt Announces Terlipressin Phase 3 Trial Achieves enrollment Target Ahead Of Schedule,2017-07-13 16:46:00-04:00,MNK,neutral
836042.0,Mallinckrodt PLC Shares Up 2% After The Company Disclosed The FDA Has Granted Orphan Drug Designation For Potential DMD Treatment,2017-07-13 08:43:00-04:00,MNK,positive
836043.0,Watching Sarepta Shares Following News Mallinckrodt Won Orphan Drug Designation For DMD Treatment,2017-07-12 16:46:00-04:00,MNK,positive
836044.0,Mallinckrodt Reports FDA Granted Orphan Drug Designation For Development Product For Potential DMD Treatment,2017-07-12 16:45:00-04:00,MNK,positive
836045.0,"Mallinckrodt Responds Following Settlement: Reaffirms 'Commitment to Ensuring Safe and Appropriate Use of its Specialty Generic Opioid Products,' Highlights 'Settlement Contains No Admission of Liability for Civil Penalties for Relevant Conduct'",2017-07-11 15:09:00-04:00,MNK,positive
836046.0,Citron Research Publishes Letter To Congress Regarding 'The Truth About Acthar',2017-06-23 09:11:00-04:00,MNK,positive
836047.0,Citron Research Tweets: $MNK Breaking News from the FDA FAERS database.  Adverse events from Acthar up over 280%  Not an opinion- FACT.   citronresearch.com,2017-06-22 10:33:00-04:00,MNK,negative
836048.0,Mallinckrodt Statement on H.P. Acthar Gel Update,2017-06-22 09:34:00-04:00,MNK,neutral
836049.0,"UPDATE: Imprimis CEO Mark Baum Tells Benzinga Eton Spin-Off Will Respond To FDA Pharma Competition Concerns, Improve Competition Against 2 'Expensive drugs without competition: Mallinckrodt's H.P. Acthar gel and Endo's Xiaflex'",2017-06-20 16:02:00-04:00,MNK,positive
836050.0,"Cantor Fitzgerald Initiates Coverage On Mallinckrodt plc Ordinary Shares with Overweight Rating, Announces $52.00 Price Target",2017-06-16 06:26:00-04:00,MNK,negative
836051.0,Mallinckrodt Enrolls 1st Patient In Phase 2B Trial Of Acthar Gel,2017-06-14 16:30:00-04:00,MNK,neutral
836052.0,"Mallinckrodt Shares Volatile Premarket As Traders Circulating Comment From Wells Fargo Suggesting Co. Is Exploring Options, Including Going Private; Stock Currently Up 1.1% But Well Off Pre-Market High",2017-06-13 08:32:00-04:00,MNK,positive
836053.0,Mallinckrodt Reports Enrollment of First Patient in Phase 3 Trial of StrataGraft,2017-06-07 07:32:00-04:00,MNK,neutral
836054.0,Intellipharmaceutics Reports Launch of Generic Seroquel XR by Mallinckrodt,2017-06-06 08:52:00-04:00,MNK,neutral
836055.0,Citron Publishes 'Citron provides New PROOF (post-SALT Conference) why Mallinckrodt is on its way to ZERO',2017-06-05 10:24:00-04:00,MNK,neutral
836056.0,Citron Research Tweets: $MNK BK  Citron exposes NEW info.  $ESRX speaks about Acthar.  Respect To Chanos.  First Enron then $VRX Now $MNK   http://citronrsearch.com,2017-06-05 10:20:00-04:00,MNK,positive
836057.0,Mallinckrodt Said To Be Exploring Sale Of Generic Drug Division,2017-05-30 16:15:00-04:00,MNK,neutral
836058.0,Mallinckrodt Shares Largely Unaffected After FDA Denies Mallinckrdot Citizens Petition Regarding INOMAX,2017-05-26 13:55:00-04:00,MNK,negative
836059.0,Mallinckrodt Announces First Patients in Prospective Observational Registry on Us of HP Acthar Gel Following Acute Multiple Sclerosis Relapse,2017-05-25 17:01:00-04:00,MNK,neutral
836060.0,Mallinckodt Reports First Patient Enrolled In Phase 4 Trial Of HP Acthar Gel For Multiple Sclerosis,2017-05-23 17:00:00-04:00,MNK,neutral
836061.0,"Mallinckrodt Spokesperson on Chanos' Short Thesis: 'Specific to Express Scripts, Mallinckrodt has arms-length contracts for services with Express Scripts'",2017-05-19 07:48:00-04:00,MNK,neutral
836062.0,"Mallinckrodt Spokesperson on Chanos' Short Thesis, Differences Between MNK-1411, Acthar: '...the regulatory path for any corticotropin-type new drug application would require FDA approval, which could take years.'",2017-05-19 07:47:00-04:00,MNK,positive
836063.0,Mallinckrodt Spokesperson on Chanos' Short Thesis: 'MNK-1411...is not a 'generic competitor to Acthar.'  They are two very different drugs.',2017-05-19 07:47:00-04:00,MNK,neutral
836064.0,"Mallinckrodt Spokesperson Refutes Chanos' Short Thesis: 'Though Acthar is a significant contributor to Mallinckrodt's overall profitability, it is substantially less than the asserted estimates'",2017-05-19 07:47:00-04:00,MNK,positive
836065.0,"Mallinckrodt Spokesperson Responds to Jim Chanos Short, Tells Benzinga His Thesis 'is not based on fact and is misleading'",2017-05-19 07:47:00-04:00,MNK,negative
836066.0,Kyniko Manager CHanos Says Alliance Between Mallinkkrodt and Express Scripts Could Hurt Investors,2017-05-18 15:05:00-04:00,MNK,negative
836067.0,"Kynikos' Jim Chanos, at SALT, Says He's Short Mallinckrodt, Express Scripts",2017-05-18 15:02:00-04:00,MNK,neutral
836068.0,"Mallinckrodt, Express Scripts Shares Make Brief Dip to Session Lows, Quickly Rebound",2017-05-18 15:01:00-04:00,MNK,positive
836069.0,"Mallinckrodt Q1 EPS $1.68 vs $1.63 Est, Sales $810.9 vs $781.2M Est",2017-05-08 06:02:00-04:00,MNK,neutral
836070.0,Mallinckrodt Announces First Patient Enrolled in Phase 2 Trial of StrataGraft,2017-05-04 16:47:00-04:00,MNK,neutral
836071.0,Wall Street Journal Reports Mallinckrodt Leaves Pharmaceutical Trade Group Ahead of Potential Changes to Bylaws,2017-04-05 11:41:00-04:00,MNK,neutral
836072.0,Mallinckrodt Says It Has Reached $35M Settlement With U.S. Over Monitoring Of Controlled Substances,2017-04-03 09:54:00-04:00,MNK,positive
836073.0,"Martin Shkreli Posts On Facebook That He Has No Position In Mallinckrodt, But 'Short Conspiracies Are Insane', Has Acthar Down 20% YoY In His Model From Here On Out And Believes Company Is Fairly Valued",2017-03-22 11:23:00-04:00,MNK,positive
836074.0,"UPDATE: Martin Shkreli Tells Benzinga 'Shorts Have Been Talking About Acthar Problems For 5 Years, Docs Swear it's A Reasonable Last-Line Treatment And I've Heard Many Testimonials About it Rescuing Patients, Much Ado About Nothing Here'",2017-03-22 10:40:00-04:00,MNK,negative
836075.0,"Hedge Fund Manager Whitney Tilson Says It's Good To See More Scrutiny Of Mallinckrodt and H.P. Acthar, Says Company Appears To Be Scummy and Scammy",2017-03-21 17:53:00-04:00,MNK,positive
836076.0,Mallinckrodt Finalizes Sale Of Its Intrathecal Therapy Business To Piramal Enterprises Limited For Approximately $203 Million,2017-03-20 07:01:00-04:00,MNK,negative
836077.0,Citron's Andrew Left  On CNBC Says Mallinckrodt Is A Small Short Position For Him Following Valeant News,2017-03-13 17:35:00-04:00,MNK,neutral
836078.0,"Mallinckrodt Shares Volatile Over Last Few Mins, Moving Lower, Despite Traders Circulating Unconfirmed Takeover Chatter",2017-03-10 12:23:00-05:00,MNK,positive
836079.0,Mallinckrodt plc Board Increases Company's Share Repurchase Plan by $1.0 Billion,2017-03-01 08:00:00-05:00,MNK,positive
836080.0,Canaccord Genuity Initiates Coverage On Mallinckrodt plc Ordinary Shares at Buy,2017-02-22 06:41:00-05:00,MNK,positive
836081.0,Recent Weakness In Mallinckrodt Being Attributed To Recently Published Business Insider Article On Acthar Gel,2017-02-16 13:50:00-05:00,MNK,negative
836082.0,"Leerink Partners Global Healthcare Conference Began Today; Presenters Include Mannkind, Universal Health Services, Celgene, Inogen, Endologix, Biogen, GW Pharma, Regulus, Fate Therapeutics, Puma Biotech, Allergan, Bristol Myers And Synergy Pharma",2017-02-15 10:29:00-05:00,MNK,neutral
836083.0,Mallinckrodt On Conf. Call Says They Expect To Realize Net Of 4.5% On The 6.9% Price Increase Of Acthar When Adjusting For Both Rebates and Discounts,2017-02-07 08:54:00-05:00,MNK,positive
836084.0,Mallinckrodt Sees FY 2017 EPS $7.40 to $8.00 vs $7.70 Est,2017-02-07 06:08:00-05:00,MNK,neutral
836085.0,"Mallinckrodt Q1 EPS $1.91 vs $1.82 Est, Revenue $829.9M vs $826.9M Est",2017-02-07 06:07:00-05:00,MNK,neutral
836086.0,Watching Shares Of Mallinckrodt As Traders Passing Around Short Piece By Agloe Capital,2017-02-06 11:17:00-05:00,MNK,positive
836087.0,"Mallinckrodt Shares Resumed, Now Up 1.05%",2017-01-27 15:40:00-05:00,MNK,positive
836088.0,Mallinckrodt Shares Halted Pending News,2017-01-27 15:27:00-05:00,MNK,positive
836089.0,"Shares Of Mallinckrodt Up 2.7% Off The Open, FDA Document Being Passed Around By Traders Regarding Acthar Gel Is A Synthetic That Was Never Marketed, Unrelated To Mallinckrodt",2017-01-19 09:32:00-05:00,MNK,positive
836090.0,Mallinckrodt Release Confirms FTC Resolution Related to Questcor Matter,2017-01-18 17:55:00-05:00,MNK,neutral
836091.0,Martin Shkreli Gives Benzinga Full Statement Following Report of Mallinckrodt Suit by FTC,2017-01-18 15:53:00-05:00,MNK,neutral
836092.0,"FTC Has Said Mallinckrodt Will Pay $100M to Settle Commission, State Charges Related to Allegations Co. Maintained Monopoly of Specialty Drugs",2017-01-18 15:46:00-05:00,MNK,negative
836093.0,Mallinckrodt Shares Halted News Pending,2017-01-18 14:46:00-05:00,MNK,positive
836094.0,"Mallinckrodt Shares Halted on Circuit Breaker, Now Down 13%",2017-01-18 14:30:00-05:00,MNK,positive
836095.0,"Mesoblast Sells 20.04M Shares to Mallinckrodt for $21.7M, Was Previously Rumored",2017-01-09 06:12:00-05:00,MNK,positive
836096.0,"Hearing Mesoblast, Mallinckrodt Entered Deal In which Mallinckrodt Will Buy 20.04M Shares of Mesoblast's Ordinary Shares at $1.4761/Share",2016-12-22 16:59:00-05:00,MNK,positive
836097.0,Raymond James Initiates Coverage On Mallinckrodt at Outperform,2016-11-18 07:22:00-05:00,MNK,neutral
836098.0,Stifel Nicolaus Initiates Coverage on Mallinckrodt at Buy,2016-08-12 07:29:00-04:00,MNK,neutral
836099.0,BMO Capital Initiates Coverage on Mallinckrodt at Outperform,2016-06-29 06:26:00-04:00,MNK,neutral
836100.0,"Goldman Sachs Initiates Coverage on Mallinckrodt at Neutral, Announces $73.00 PT",2016-06-06 07:23:00-04:00,MNK,neutral
836101.0,"Piper Jaffray Maintains Overweight on Mallinckrodt, Raises PT to $102.00",2016-05-03 15:23:00-04:00,MNK,negative
836102.0,"RBC Capital Maintains Outperform on Mallinckrodt, Raises PT to $218.00",2016-03-28 08:00:00-04:00,MNK,neutral
836103.0,Wells Fargo Initiates Coverage on Mallinckrodt at Outperform,2016-02-19 08:40:00-05:00,MNK,positive
836104.0,Mizuho Securities Upgrades Mallinckrodt to Buy,2016-02-03 06:10:00-05:00,MNK,positive
836105.0,"Morgan Stanley Upgrades Mallinckrodt to Overweight, Raises PT to $88.00",2015-12-03 07:17:00-05:00,MNK,negative
836106.0,Mallinckrodt Study Shows Acthar Primary Endpoint Not Met in Patients with Persistently Active Systemic Lupus Erythematosus,2015-11-09 06:42:00-05:00,MNK,positive
836107.0,"Northland Securities Initiates Coverage on Mallinckrodt at Outperform, Announces $92.00 PT",2015-10-14 08:14:00-04:00,MNK,positive
836108.0,UPDATE: Mallinckrodt Pharmaceuticals to Acquire Therakos from Gores Group for $1.325B,2015-08-10 05:02:00-04:00,MNK,neutral
836109.0,"JP Morgan Downgrades Mallinckrodt to Neutral, Lowers PT to $120.00",2015-08-05 07:21:00-04:00,MNK,positive
836110.0,Bellerophon Therapeutics Expands License Agreement With INO Therapeutics,2015-07-29 06:04:00-04:00,MNK,positive
836111.0,"Goldman Sachs Reinstates Neutral on Mallinckrodt, Announces $131.00 PT",2015-04-28 11:48:00-04:00,MNK,neutral
836112.0,Mallinckrodt Pharmaceuticals to Acquire Ikaria for $2.3B,2015-03-05 07:02:00-05:00,MNK,neutral
836113.0,"JP Morgan Upgrades Mallinckrodt to Overweight, Raises PT to $130.00",2015-02-13 06:21:00-05:00,MNK,neutral
836114.0,"BMO Capital Downgrades Mallinckrodt to Market Perform, Maintains $95.00 PT",2015-01-06 06:30:00-05:00,MNK,neutral
836115.0,Mallinckrodt PLC Reports Q4 EPS of $1.68 vs $1.41 Est; Revenue of $789.30M vs $757.86M Est,2014-11-19 07:00:00-05:00,MNK,neutral
836116.0,"Morgan Stanley Maintains Equal-weight on Mallinckrodt PLC, Announces $97.00 PT",2014-10-15 05:47:00-04:00,MNK,neutral
836117.0,Mallinckrodt PLC Sees FY2014 EPS $6.70-7.20 vs $6.63 Est; Sees Sales $3.65B-3.75B,2014-10-14 07:04:00-04:00,MNK,neutral
836118.0,"Barclays Reinstates Overweight on Mallinckrodt PLC, Announces $105.00 PT",2014-09-22 05:41:00-04:00,MNK,negative
836119.0,Mallinckrodt PLC Reports Q3 EPS of $1.20 Which May Not Compare $0.87 Est; Revenue of $653.10M Which May Not Compare $278.83M Est,2014-08-07 07:15:00-04:00,MNK,neutral
836120.0,"Oppenheimer Initiates Coverage on Mallinckrodt PLC at Outperform, Announces $100.00 PT",2014-07-16 19:19:00-04:00,MNK,neutral
836121.0,Mallinckrodt Reports Q2 Adjuted EPS of $0.95 vs $0.77 Est; Revenue of $557.80M vs $566.48M Est,2014-05-08 06:07:00-04:00,MNK,neutral
836122.0,"CRT Capital Upgrades Mallinckrodt PLC to Fair Value, Raises PT to $70.00",2014-04-25 08:55:00-04:00,MNK,positive
836123.0,"CRT Capital Upgrades Mallinckrodt PLC to Fairly Valued, Raises PT to $70.00",2014-04-24 13:52:00-04:00,MNK,positive
836124.0,"UBS Upgrades Mallinckrodt PLC to Buy, Raises PT to $84.00",2014-04-09 09:17:00-04:00,MNK,neutral
836125.0,"BMO Capital Upgrades Mallinckrodt PLC to Outperform, Raises PT to $71.00",2014-04-08 08:05:00-04:00,MNK,neutral
836126.0,Mallinckrodt to Acquire Questcor Pharmaceuticals for $5.6B,2014-04-07 07:10:00-04:00,MNK,neutral
836127.0,"Morgan Stanley Downgrades Mallinckrodt PLC to Equal-weight, Removes $63.00 PT",2014-02-12 06:57:00-05:00,MNK,neutral
836128.0,UPDATE: Mallinckrodt to Acquire Cadence Pharmaceuticals for $14.00/Share in Cash ,2014-02-11 07:09:00-05:00,MNK,neutral
836129.0,"Morgan Stanley Maintains Overweight on Mallinckrodt PLC, Raises PT to $63.00",2014-02-07 07:05:00-05:00,MNK,negative
836130.0,"Mallinckrodt, Medtronic Announce Clinical and Commercial Collaboration ",2014-01-13 08:30:00-05:00,MNK,neutral
836131.0,"Morgan Stanley Initiates Coverage on Mallinckrodt PLC at Overweight, Announces $60.00 PT",2014-01-08 06:35:00-05:00,MNK,negative
836132.0,"Buckingham Research Initiates Coverage on Mallinckrodt PLC at Buy, Announces $63.00 PT",2013-12-04 07:38:00-05:00,MNK,neutral
836133.0,"Jefferies Initiates Coverage on Mallinckrodt PLC at Buy, Announces $60.00 PT",2013-11-26 06:31:00-05:00,MNK,neutral
836134.0,Mallinckrodt PLC Reports Q4 EPS of $1.02 vs $0.85 Est; Revenue of $552.20M vs $572.57M Est,2013-11-07 07:19:00-05:00,MNK,neutral
836135.0,"Goldman Sachs Initiates Coverage on Mallinckrodt PLC at Neutral, Announces $45.00 PT",2013-09-17 07:09:00-04:00,MNK,neutral
836136.0,Mallinckrodt PLC Reports Q3 EPS of $0.49 vs $0.78 Est; Revenue of $570.0M vs $560.17M Est,2013-08-09 07:32:00-04:00,MNK,neutral
836137.0,UPDATE: Barclays Capital Initiates Mallinckrodt at Equal-Weight on Differentiated Platform Value,2013-07-08 08:57:00-04:00,MNK,positive
836138.0,UPDATE: Bank of America Initiates Mallinckrodt with Buy on Brand Launch Potential,2013-07-03 08:35:00-04:00,MNK,neutral
836139.0,Mallinckrodt Begins Trading on NYSE,2013-07-01 07:05:00-04:00,MNK,neutral
